Camilla Soenderby was appointed Chief Patient Value & Product Strategy Officer for Takeda in January 2019. Having joined Shire in March 2018, Camilla led and oversaw Global Product Strategy, which comprised six franchises (rare diseases and specialty conditions) as well as Global Market Access, Global Patient Services and Global Commercial Operations. Camilla chaired the company’s In-line Committee, which was responsible for delivering maximum value and managing the commercial performance of all marketed and pipeline brands, as well as for making commercial resourcing tradeoffs and overseeing supply from a commercial perspective. In addition, she was a member of Shire’s Pipeline Committee.
Camilla has extensive international leadership and management experience in the biopharmaceutical industry. She has held various strategic and operational roles with full P&L responsibility in both established and emerging markets. She has broad expertise in building, leading and motivating teams in a multinational environment and fostering a culture of collaboration and innovation.
Prior to her role as Head of Global Product Strategy, she was Region Head for Roche Pharma with P&L responsibility for 11 countries in Central, South and Eastern Europe ($1.5 bio in revenue, 1,500 people). Prior to that, she worked as General Manager for Abbott (now AbbVie), first in Sweden and later in the United Kingdom. She also held several operational and strategic roles of increasing responsibility at Schering Plough in Asia Pacific, including General Manager for Taiwan. Before that, Camilla was as a management consultant at McKinsey & Company focusing on the bio-pharmaceutical and medical device industries.
Camilla earned a Master’s Degree in Political Science from the University of Copenhagen and completed McKinsey’s mini MBA program led by faculty from Harvard and INSEAD.